Estradiol benzoate/testosterone isobutyrate explained

Estradiol benzoate/testosterone isobutyrate (EB/TiB), sold under the brand names Femandren M and Folivirin, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone isobutyrate (TiB), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women.[1] [2] [3] [4] [5] [6] [7] It is provided in the form of 1 mL ampoules containing 2.5 mg estradiol benzoate and 25 mg testosterone isobutyrate in a microcrystalline aqueous suspension and is administered by intramuscular injection once every 4 to 6 weeks.[8] EB/TiB reportedly has a duration of about 14 to 21 days.[9]

The medication is available only in the Czech Republic and Slovakia.[10] [11] [12] [13] EB/TiB was originally developed and marketed by the Swiss pharmaceutical company Ciba and was introduced for medical use by 1953, following the development of testosterone isobutyrate in 1952.[14] It was intermittently manufactured by Spofa[15] and then Biotika and is now manufactured by BB Pharma.[16]

The effect of EB/TiB on gonadotropin levels in postmenopausal women have been studied.[17]

An oral tablet product with the same brand name of Femandren, containing ethinylestradiol and methyltestosterone, was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.[18]

See also

Notes and References

  1. Web site: FOLIVIRIN Injekční suspenze, Příbalová Informace - Informace Pro Uživatele . FOLIVIRIN Suspension for injection, Package Information - Information For Users . Biotika A.S. . State Institute for Drug Control . Czech Republic . Czech . 2019-05-20 . 2019-05-20 . https://web.archive.org/web/20190520031642/http://www.sukl.cz/download/pil/PI15789.pdf . dead .
  2. Kubíková D . . Menopausal symptoms and hormone replacement therapy . cs . 2014 . Praktické Lékárenství . 10 . 2 . 68–73 . 1801-2434 . http://www.solen.sk/pdf/95e898d92100a736e32110dd1b846a9e.pdf-->.
  3. Book: Josef M . Farmakoterapie endokrinních onemocnění a léčba kortikosteroidy . Pharmacotherapy of endocrine diseases and treatment with corticosteroids . Farmakoterapie vnitřních nemocí . 4th . Pharmacotherapy of internal diseases . https://books.google.com/books?id=bUqECwAAQBAJ&pg=PA380. 14 May 2010. Grada Publishing a.s.. 978-80-247-9524-9. 380–. In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect..
  4. Book: Arends G, Zörnig H, Hager H, Frerichs G, Kern W . Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. 14 December 2013. Springer-Verlag. 978-3-662-36329-4. 1163–.
  5. Book: Hager HH, Kern W, List PH, Roth HJ . Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). 29 July 2013. Springer-Verlag. 978-3-662-25655-8. 109, 141, 178, 185.
  6. Book: Ciba Symposium: 1953/57:Index. 1953. Ciba. 197. Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines..
  7. Aeppli H, Herrmann FU . Kombinierte Androgen-Oestrogenbehandlung mit Kristallsuspensionen. Gynecologic and Obstetric Investigation. 136. 5. 1953. 290–295. 1423-002X. 10.1159/000308340.
  8. Book: Horsky J, Presl J . Climacteric and Menopause . Ovarian Function and its Disorders: Diagnosis and Therapy. https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA146 . 6 December 2012. Springer Science & Business Media. 978-94-009-8195-9. 146–.
  9. Book: Ufer J . Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis . Hormone Therapy in Gynecology: Principles and Practice . 5th . de . 1 January 1978 . 978-3110066647 . 924728827 . de Gruyter . 276.
  10. Web site: Estradiol: Uses, Dosage & Side Effects . Drugs.com .
  11. Web site: Testosterone Injections: Uses, Side Effects & Warnings . Drugs.com .
  12. Book: Sweetman SC . Sex hormones and their modulators . Martindale: The Complete Drug Reference . 36th . 2009 . 2133–2134 . Pharmaceutical Press . London . 978-0-85369-840-1.
  13. Web site: Home . micromedexsolutions.com.
  14. Drescher H . Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension . Experiences with a New Testosterone Isobutyrate Crystal Suspension . de . Dtsch. Med. Wochenschr. . 77 . 14 . 431–2 . April 1952 . 12988767 . 10.1055/s-0028-1115985 . 260092180 .
  15. Book: Schreiber V . Thyroxine Binding to Anterior Pituitary Proteins in Vitro: Correlation with Anterior Pituitary Growth . Lissak K . Hormones and Brain Function. https://books.google.com/books?id=7wX3BwAAQBAJ&pg=PA145. 6 December 2012. Springer Science & Business Media. 978-1-4684-2007-4. 145– . 10.1007/978-1-4684-2007-4_14 .
  16. Web site: Folivirin Injection . bbpharma.sk.
  17. Talas M, Gazárak F, Stehliková J, Lubuský D, Fingerová H . FSH- und LH-Spiegel im Serum von Frauen nach chirurgischer Kastration und bei hormonaler Behandlung von Ausfallsbeschwerden . Serum FSH and LH levels in women following surgical castration and during hormonal management of menopause symptoms . de . Zentralbl Gynakol . 97 . 25 . 1580–7 . 1975 . 0044-4197 . 1227215 .
  18. Book: Kahr H, Müller HA . Konservative Therapie der Frauenkrankheiten. Behandlung der Menstruationsstörungen. 1956. 1–85. Springer . 10.1007/978-3-7091-5694-0_1. 978-3-7091-5696-4.